Pharma Company Venus Remedies Joins AMR Industry Alliance

Pharma firm Venus Remedies on Monday said it has joined AMR Industry Alliance - a league of over 100 globally renowned organisations - to develop solutions to combat the grave public health threat posed by antimicrobial resistance.

Welcoming Venus Remedies as a new member, Melissa Mitchell, Secretariat Lead of AMR (antimicrobial resistance) Industry Alliance, said, We are delighted to have Venus Remedies join our ranks".

"As an organisation, they lead by example and make commendable efforts to counter the threat of AMR by improving the access of AMR-relevant drugs to third-world countries and encouraging appropriate antibiotic use, along with good stewardship activities.

"Leading companies in the life science sector, like Venus Remedies, are playing a vital role in the mitigation of AMR and continue to strengthen multi-stakeholder collaborations," Mitchell said in the statement.

AMR Industry Alliance is the largest private-sector coalition working towards curbing AMR through a coordinated and multipronged response.

Since its inception in 2017, it has been persistently contributing towards sustainable solutions to curb AMR by creating a broad industry momentum and facilitating collaboration between the public and private sectors.

The alliance membership comprises R&D-based pharmaceutical, generics, diagnostics and biotechnology companies, apart from industry associations.

In addition to promoting innovation to prevent, diagnose and treat drug-resistant infections, this global coalition is checking the emergence of resistance through appropriate use, addressing barriers to patient access to appropriate drugs and advancing responsible manufacturing.

It is an honour to collaborate with the global life sciences industry under the aegis of the AMR Industry Alliance and devise sustainable solutions to AMR.

"I hope this association will amplify our existing efforts against AMR at a global level by shaping relevant AMR policies and plugging the leaks in the current antibiotic research and manufacturing landscape with a focus on access and appropriate use," Saransh Chaudhary, CEO, Venus Medicine Research Centre (VMRC), said.

The AMR Industry Alliance membership of Venus Remedies, which has played a commendable role in ensuring appropriate manufacturing and access of antibiotics, is part of the company's ongoing efforts to join hands with other organisations in a determined fight against AMR at a global scale, the statement said.

Having a presence in 80 countries, Venus Remedies has enabled the sustainable supply of quality-assured antibiotics to the countries, which did not have easy access to them, Chaudhary said.

"Venus Remedies is among the very few R&D-based pharma firms in the world focusing on AMR for over a decade now. Many of its superbug-tackling solutions and last-line generic antibiotics have helped millions of patients and prevented the spread of bacterial resistance from one species to another," the company said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor